Corcept Therapeutics Inc. is a pharmaceutical company focused on the research, development, and commercialization of treatments for severe metabolic, oncologic, and neuropsychiatric disorders within the United States. Their primary commercial product, Korlym (mifepristone) tablets, is an oral medication administered once daily. It targets hyperglycemia stemming from hypercortisolism in adult patients with endogenous Cushing's syndrome, particularly those with type 2 diabetes or glucose intolerance who have either failed or are unsuitable for surgical intervention.